Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of cluster headache as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of \>=1 month.~* Participants are able to distinguish cluster headache attacks from other headaches.~Exclusion Criteria:~* Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device.~* Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).~* Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia.~* A history of migraine variants that could implicate or could be confused with ischemia.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.~* A history or presence of other medical illness that indicates a medical problem that would preclude study participation.~* Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 300mg (Type: EXPERIMENTAL): Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC every 30 days during an 8 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).